MJ Gleeson plc (GLE)
London Stock Exchange · UK · prices in GBX · close of 27 Oct 2026
Key indicators
| Last close | GBX 294.00 |
|---|---|
| 52-week range | 221.00 – 435.00 |
| Return, 1 month / 3 months | +20.7% / +8.3% |
| Return, 1 year / 3 years | −18.5% / −21.8% |
| Trend | Uptrend |
| RSI (14) | 62 |
| Volatility (1 year) | 42.4% |
| Worst drawdown (1 year) | -47.6% |
| Average daily value traded | 21.41M GBX |
| Dividend yield | 1.7% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
MJ Gleeson plc is a British housebuilder based in Sheffield. Through its Gleeson Homes division it builds new homes aimed at first-time buyers and lower-income households, mainly in the north of England and the Midlands. Its strategic land division buys land, works to secure planning permission for residential use, and then sells that land on to other housebuilders. The company serves homebuyers and the wider housing market in England.
On this site MJ Gleeson plc appears as a stock on the London Stock Exchange (UK), code GLE, with prices in pence sterling (GBX). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
MJ Gleeson plc (GLE) trades on the London Stock Exchange in UK. It last closed at GBX 294.00 on 27 October 2026.
Its price-based Market X-Ray is 50 out of 100 (a weak price profile), ranking 2,091 of 3,788 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 18.5% and over the last three months it rose 8.3%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 41 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | 4.5% | ||
| From 52-week high | -31.1% | ||
| Momentum | 57 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 8.3% | ||
| 6-month return | 23.5% | ||
| 12-month return, skipping the last month | -32.5% | ||
| Stability (higher is calmer) | 30 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 42.4% | ||
| Worst drawdown, 1 year (smaller is calmer) | -47.6% | ||
| Liquidity | 80 · Strong | Trades actively. | |
| Average daily value traded | 21.41M GBX | ||
| Zero-volume days | 0.0% | ||
| Income | 57 · Fair | Dividend is typical for this exchange. | |
| Dividend yield | 1.7% | ||
| Years with dividends | 6 |
Strengths
- Liquidity: Trades actively.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | +4.3% |
|---|---|
| 1 month | +20.7% |
| 3 months | +8.3% |
| 6 months | +23.5% |
| 1 year | −18.5% |
| 3 years | −21.8% |
| 5 years | −57.0% |
Signals
| 50-day / 200-day average | 268.57 / 281.40 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 13.76 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 22 Oct 2026 | GBP 0.0100 |
| 5 Mar 2026 | GBP 0.0400 |
| 23 Oct 2025 | GBP 0.0700 |
| 6 Mar 2025 | GBP 0.0400 |
| 24 Oct 2024 | GBP 0.0700 |
| 29 Feb 2024 | GBP 0.0400 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.